Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 225 results

Music and Health: Understanding And Developing Music Medicine (R21 Clinical Trial Optional)

PAR
Wednesday, December 23, 2020
Friday, February 17, 2023
R21
PAR-21-099
Robert Riddle

Funding Opportunity Purpose

This FOA is intended to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders.

Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)

PAR
Monday, December 21, 2020
Wednesday, September 13, 2023
U54
PAR-20-316
David A. Jett

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy consistent with the product's intended use in humans. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, and a research education core. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan.

New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research Exploration (ASPIRE) Collaborative Research Program (UG3/UH3 Clinical Trials Not Allowed)

RFA
Sunday, December 20, 2020
Heal
Friday, July 9, 2021
UG3/UH3
RFA-TR-21-001

Funding Opportunity Purpose

The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance the ability to discover and develop new chemistries towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural scientists have established an integrated NCATS ASPIRE platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. The FOA will support intramural - extramural collaborations to develop additional physical modules that will enhance the platform’s capabilities. The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting points for drug development of novel targets, and the expansion of chemical space available for drug screening.

Virtual Approaches Towards New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research Exploration (ASPIRE) Collaborative Research Program (U18 Clinical Trials Not Allowed)

RFA
Thursday, December 10, 2020
Heal
Friday, July 9, 2021
U18
RFA-TR-21-002

Funding Opportunity Purpose

The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance our ability to discover and develop new chemistries designed towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural scientists have established an integrated platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. This FOA will support intramural - extramural collaborations to develop virtual modules that will enhance the platform’s capabilities (see companion FOA RFA-TR-21-001 for physical modules). The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting points for drug development of novel targets, and the expansion of chemical space available for drug screening.

Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

PAR
Monday, November 23, 2020
Clinical Trials Research
Monday, January 8, 2024
R01
PAR-21-068
May Wong

Funding Opportunity Purpose

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.

Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

PAR
Monday, November 23, 2020
Clinical Trials Research
Monday, January 8, 2024
R21
PAR-21-069

Funding Opportunity Purpose

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Studies that move the science of HIV and aging into new directions with little or no preliminary data are appropriate for this activity code.

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

PAR
Thursday, November 19, 2020
Friday, September 8, 2023
U44
PAR-21-057

Funding Opportunity Purpose

The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)

PAR
Thursday, November 19, 2020
Friday, September 8, 2023
U01
PAR-21-056

Funding Opportunity Purpose

The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

PAR
Thursday, November 19, 2020
Friday, September 8, 2023
U01
PAR-21-058

Funding Opportunity Purpose

The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)

PAR
Thursday, November 19, 2020
Friday, September 8, 2023
U44
PAR-21-059

Funding Opportunity Purpose

The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

Pages